Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
5.21.25
Wilson Sonsini Advises Halo Labs on Acquisition by Waters
On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Bolt Medical on Merger with Boston Scientific
On January 8, 2025, Boston Scientific announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease, for up to $900 million. Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction.
Client Highlights
12.23.24
Wilson Sonsini Advises USANA Health Sciences on Acquisition of Hiya Health
On December 23, 2024, USANA Health Sciences announced the acquisition of a 78.8 percent controlling ownership stake in Hiya Health Products, a leading direct-to-consumer provider of high-quality children’s health and wellness products. The $205 million cash transaction was completed on the same date and is anticipated to be accretive to USANA’s 2025 adjusted EBITDA. Wilson Sonsini Goodrich & Rosati advised USANA on the transaction.
Client Highlights
6.20.24
Firm Advises Silk Road Medical on $1.26 Billion Acquisition by Boston Scientific
On June 18, 2024, Silk Road Medical announced that it entered into a definitive agreement to be acquired by Boston Scientific Corporation for a purchase price of $27.50 per share, reflecting an aggregate equity value of approximately $1.26 billion. Silk Road Medical is a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). Wilson Sonsini Goodrich & Rosati advised Silk Road Medical on the transaction.
Alerts
12.11.23
International Guiding Principles and Cybersecurity Guidelines for AI Actors Adopted by G7 and Other Major Economies
During the last weeks of 2023, the international community announced several initiatives designed to establish common standards for AI actors to implement in their development and use of AI. On October 30, 2023, the leaders of the G7 released International Guiding Principles and a Code of Conduct for organizations developing and using advanced AI systems. The following month, the cybersecurity authorities of the UK, the U.S., and more than a dozen other major economies published the Guidelines for Secure AI System Development on November 27, 2023. While not legally binding, these instruments define proposed best practices for developing trustworthy AI, establish an international understanding of the risks and mitigation strategies related to AI systems, and complement national laws regulating AI.
Client Highlights
9.12.23
Wilson Sonsini Advises Insilico Medicine on $80 Million Agreement with Exelixis
On September 12, 2023, Exelixis, Inc. and Insilico Medicine announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80 million anticipated in the third quarter 2023. Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
Client Highlights
8.29.23
Wilson Sonsini Represents Thorne HealthTech in Sale to L Catterton
On August 28, 2023, Thorne HealthTech, Inc., a leader in delivering innovative solutions for a personalized approach to health and wellness, announced that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused investment firm, will commence a tender offer to acquire all outstanding shares of common stock of Thorne for $10.20 per share in cash. The transaction value of approximately $680 million represents a 94 percent premium to the unaffected closing share price on July 20, 2023, and a 113 percent premium to the 30-day volume weighted average price as of the unaffected date of July 20, 2023. Thorne's independent Special Committee and board of directors have each unanimously approved the agreement and recommend that Thorne’s stockholders tender their shares into the tender offer. Wilson Sonsini Goodrich & Rosati represented Thorne and the Special Committee of the board of directors in the transaction.
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes:
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes: